In January 2019, Health Guard and Liaoning Chengda Biotechnology Co., Ltd. entered into a collaboration agreement on the development and commercialization of the 15-valent HPV vaccine candidate developed by Health Guard. Chengda Bio. will take charge of clinical development and commercialization of the 15-valent HPV during the license period as set forth in the agreement.